“Pfizer” company raised expectations about increasing its revenues for this year, through a huge launch of its vaccine against Covid-19, in addition to the strong performance achieved by other sectors of this medical company.
The company reported first-quarter earnings of $ 4.88 billion, or 86 cents per share. And earnings per share were 93 cents, if one-off costs or gains were removed. That’s well above Wall Street’s forecast of 79 cents, according to a Sachs Investment Research Survey.
Revenue came to $ 14.58 billion, easily beating analyst expectations of $ 13.49 billion.
Pfizer expects its year-end earnings of $ 3.65 per share, with revenues between $ 70.5 billion and $ 72.5 billion.
Pfizer also stated that this year it may produce two billion doses of the emerging coronavirus vaccine, which it developed in partnership with the German company Biontech, including the 200 million doses promised by the United States by the end of May.
The New York-based company is manufacturing hundreds of millions of doses of the vaccine against Covid-19, and is pressing ahead with research that measures its effectiveness in different categories of patients, such as teenagers and people with weakened immune systems.
Source: Associated Press